Both experimental results and network pharmacology predictions confirmed that daidzein and luteolin may inhibit PI3K-AKT signaling pathway-mediated endogenous apoptosis, which suggests that RJJD has a pharmacological basis for the treatment of LPS-induced ALI. The gene discussed is AKT1; the disease is acute respiratory distress syndrome.